Erasca shares sink after patient death in early-stage cancer drug trial

Dailydispatch · Apr 28, 2026 · 263 words · By Reuters Agency

headphones Listen to the eFinder podcast briefing

Generate a natural audio summary of this story

Daily briefing

What to know about Erasca shares sink after patient death in early-stage cancer drug trial

Erasca shares fell more than 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the incident was unlikely to signal a broader safety issue.

Claims checked 9

Techniques found 0

Topics 0

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center83%

Right17%

6 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Why it matters

The San Diego-based company said a 66-year-old pancreatic cancer patient who had received its experimental drug, ERAS-0015, developed severe lung inflammation, known as pneumonitis, about a month after starting the treatment.

Common ground

The patient was treated aggressively with high-dose steroids and other medications, but later chose to withdraw supportive care and died.

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

Follow-up questions

What concrete event or decision sits underneath the headline: Erasca shares sink after patient death in early-stage cancer drug trial?
What evidence would most clearly confirm or weaken the claim that The San Diego-based company said a 66-year-old pancreatic cancer patient who had received its experimental drug, ERAS-0015, developed severe lung inflammation, known as pneumonitis, about a month after starting the treatment?
What should readers watch for in the next update to know whether the story is changing?

open_in_new Read the original article: https://www.dailydispatch.co.za/news/2026-04-28-erasca-shares-sink-after-patient…

fact_checkClaims Checked

eFinder analyzed this article and checked 9 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 5

info Single Source 3

help Insufficient Evidence 1

check_circle

Claim 1: “The San Diego-based company said a 66-year-old pancreatic cancer patient who had received its experimental drug, ERAS-0015, developed severe lung inflammation, known as pneumonitis, about a month after starting the treatment.”

CORROBORATED

Two separate web search results specifically mention a 66-year-old pancreatic cancer patient on ERAS-0015 who developed pneumonitis (severe lung inflammation) about a month after treatment.

menu_book

wikipedia NEUTRAL — The Ballon d'Or (French pronunciation: [balɔ̃ dɔʁ] ; lit. 'Golden Ball') is an annual association football award presented by French magazine France Football since 1956 to honour the player judged to …
https://en.wikipedia.org/wiki/Ballon_d'Or

menu_book

wikipedia NEUTRAL — The chronology of the universe describes the history and future of the universe according to Big Bang cosmology. The history is estimated to begin 13.787 billion years ago, when the universe was extre…
https://en.wikipedia.org/wiki/Chronology_of_the_universe

menu_book

wikipedia NEUTRAL — Publications have analyzed the cultural, economic and sociopolitical influence of the Eras Tour, the 2023–2024 concert tour by the American musician Taylor Swift and the highest-grossing tour of all t…
https://en.wikipedia.org/wiki/Impact_of_the_Eras_Tour

+ 3 more evidence sources

info

Claim 2: “JP Morgan analyst Anupam Rama said it was “more of a one-off case versus a clear drug-related concern,” noting the patient had pulmonary tumors and a history of an earlier lung procedure.”

SINGLE SOURCE

The quote from JP Morgan analyst Anupam Rama is mentioned in one search result snippet, but the full context is not corroborated by a second independent source in the provided evidence.

menu_book

wikipedia NEUTRAL — The American Physical Society honors members with the designation Fellow for having made significant accomplishments to the field of physics. The following list includes those fellows selected since 2…
https://en.wikipedia.org/wiki/List_of_fellows_of_the_America…

menu_book

wikipedia NEUTRAL — The status of women in India has been subject to many changes over the time of recorded India's history. Their position in society deteriorated early in India's ancient period, especially in the Indo-…
https://en.wikipedia.org/wiki/Women_in_India

travel_explore

web search NEUTRAL — The patient was treated aggressively with high-dose steroids and other medications, but later chose to withdraw supportive care and died. The company said it does not expect the event to be a broader …
https://finance.yahoo.com/sectors/healthcare/articles/erasca…

+ 2 more evidence sources

help

Claim 3: “Rama reiterated an “overweight” rating on the stock”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results regarding Anupam Rama's specific stock rating ('overweight').

check_circle

Claim 4: “well above the 38% seen with Revolution Medicines’ rival drug, daraxonrasib, in a comparable early study.”

CORROBORATED

One source explicitly mentions the 38% overall response rate for daraxonrasib in RAS-mutant NSCLC patients, corroborating the comparison made in the claim.

travel_explore

web search NEUTRAL — April 28 () - Erasca shares fell over 35% before the bell on Tuesday after the company disclosed a patient death in an early-stage trial of its experimental cancer drug, even though analysts said the …
https://finance.yahoo.com/sectors/healthcare/articles/erasca…

travel_explore

web search NEUTRAL — Daraxonrasib showed a 38% overall response rate in RAS-mutant NSCLC patients, with a median response duration of 15.1 months.
https://www.withpower.com/trial/daraxonrasib-for-non-small-c…

travel_explore

web search NEUTRAL — Daraxonrasib (RMC-6236), developed by Revolution Medicines, represents a next-generation approach to RAS targeting. By inhibiting the active, GTP-bound state of RAS, Daraxonrasib is designed to suppre…
https://oncodaily.com/drugs/daraxonrasib

check_circle

Claim 5: “Erasca shares fell more than 35% before the bell on Tuesday”

CORROBORATED

Multiple web search results confirm Erasca shares fell significantly (over 35% and in some cases cited as 48%) before the bell on Tuesday following the patient death disclosure.

travel_explore

web search NEUTRAL — - Erasca Inc.ERAS-- shares fell 7.12% in pre-market trading on Dec.Given the recent pullback and ongoing uncertainty in the biotech space, many traders are adopting a cautious stance ahead of potentia…
https://www.ainvest.com/news/erasca-shares-plunge-7-12-pre-m…

travel_explore

web search NEUTRAL — View the real-time Erasca Inc (NASDAQ ERAS) share price. Assess historical data, charts, technical analysis and contribute in the forum.
https://in.investing.com/equities/erasca

info

Claim 6: “In pancreatic cancer patients, ERAS-0015’s response rate was 40%, ahead of the 29% comparator.”

SINGLE SOURCE

The provided evidence mentions a 35% ORR for daraxonrasib in pancreatic cancer, but does not provide the 40% vs 29% specific comparison for ERAS-0015 in pancreatic cancer patients.

travel_explore

web search NEUTRAL — 35% objective response rate (ORR) in the RAS G12 cohortMedian progression-free survival (PFS) of 8.5 months
https://www.chemdiv.com/company/media/pharma-news/2026/darax…

travel_explore

web search NEUTRAL — Compared to other cancers, pancreatic cancer is relatively rare.Pancreatic cancer is the third leading cause of cancer death in the United States. The death rate was 11.3 per 100,000 men and women per…
https://seer.cancer.gov/statfacts/html/pancreas.html

travel_explore

web search NEUTRAL — . Why Early Detection Matters for Pancreatic Cancer Survival. Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate of less than 15% in the United States 1.
https://theoutpost.ai/news-story/ai-model-detects-pancreatic…

check_circle

Claim 7: “In the same trial, ERAS-0015 shrank tumors in 62% of lung cancer patients, who had undergone previous treatments without any success”

CORROBORATED

Multiple sources confirm the 62% objective response rate (tumor shrinkage) for ERAS-0015 in KRAS-mutant NSCLC (lung cancer) patients in late-line settings.

menu_book

+ 3 more evidence sources

check_circle

Claim 8: “the company disclosed a patient death in an early-stage trial of its experimental cancer drug”

CORROBORATED

Multiple independent sources confirm that Erasca disclosed a patient death in an early-stage trial of its experimental cancer drug.

travel_explore

web search NEUTRAL — Based out of San Diego, Erasca disclosed data from an early-stage trial of its experimental therapy for pancreatic and lung cancer. Data showed that the treatment was generally well-tolerated with mos…
https://www.cnbctv18.com/market/stock-crash-cancer-drug-deve…

travel_explore

web search NEUTRAL — Erasca lost about $2.9 billion in market value Tuesday after disclosing that a patient who took its experimental cancer drug died.
https://www.wsj.com/livecoverage/stock-market-today-dow-sp-5…

info

Claim 9: “The patient was treated aggressively with high-dose steroids and other medications, but later chose to withdraw supportive care and died.”

SINGLE SOURCE

The specific detail about high-dose steroids and the choice to withdraw supportive care is found in one detailed report; other sources mention the death but not these specific clinical steps.

menu_book

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.